Disc Medicine: Differentiated EPP Therapy and Asymmetric FDA Catalyst Support Buy Rating

Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Disc Medicine and keeping the price target at $120.00.

Sean Laaman has given his Buy rating due to a combination of factors tied to Disc Medicine’s lead asset, bitopertin, and its upcoming regulatory decision. He views bitopertin as a differentiated, orally administered, disease-modifying therapy that can meaningfully improve on existing treatment options for erythropoietic protoporphyria (EPP), a condition with substantial unmet medical need. His team’s conversations with experts suggest strong potential uptake if the drug is approved, given that many patients are expected to prefer bitopertin as a first-line option over the current standard, which is less convenient and faces access hurdles. Based on these assumptions, he models peak sales significantly above market consensus, supporting a more favorable long-term revenue outlook for the company.

In addition, Laaman believes the upcoming FDA decision represents an asymmetric risk/reward setup for the stock. While recognizing inherent regulatory uncertainty, he assigns a high probability of approval and expects a substantial share price appreciation if the decision is positive. Even in less favorable regulatory scenarios, he notes that management has clear contingency plans, including the potential use of future confirmatory data to support resubmission, which helps preserve the asset’s value. Taken together, the sizable commercial opportunity, strong expert support, and favorable risk/reward around the imminent catalyst underpin his Buy rating on Disc Medicine.

In another report released on January 28, BMO Capital also maintained a Buy rating on the stock with a $120.00 price target.